This inventor holds 3 USPTO granted patents and 1 published patent application and 2 EPO patents. Top assignee: Wuhan Ll Science and Technology Development Co., Ltd.. Active years: 2025.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2025
Title: Innovations of Wei Peng in Pharmaceutical Development
Introduction
Wei Peng is a notable inventor based in Hubei, China. He has made significant contributions to the field of pharmaceutical development, particularly in the area of lysophosphatidic acid receptor antagonists. With a total of two patents to his name, his work demonstrates a commitment to advancing medical science and improving treatment options for various diseases.
Latest Patents
Wei Peng's latest patents include a lysophosphatidic acid receptor antagonist and a preparation method for it. These compounds exhibit high LPAR1 antagonist activity and selectivity, along with low toxicity and good metabolic stability. They hold promising prospects for pharmaceutical development and may be utilized in preventing or treating LPAR1-related diseases. The IC50 values of some compounds can be as low as 300 nM or even below 50 nM, while the CC50 value range can reach 200 μM or above. Additionally, these compounds demonstrate good metabolic stability in humans, mice, and rats.
Another significant patent by Wei Peng involves triazole compounds and their preparation method. These triazole compounds also show good LPAR1 antagonistic activity and selectivity, low toxicity, and good metabolic stability. They can be used for preventing or treating LPAR1-related diseases or disorders. The IC50 values of some triazole compounds can be below 300 nM, even reaching 50 nM. The CC values of these compounds can exceed 200 μM, and they exhibit good metabolic stability in humans, fancy rats, and house mice.
Career Highlights
Wei Peng is currently associated with Wuhan Ll Science and Technology Development Co., Ltd. His work at this company has allowed him to focus on innovative research and development in the pharmaceutical sector. His contributions have been instrumental in advancing the understanding and treatment of diseases related to lysophosphatidic acid receptors.
Collaborations
Wei Peng collaborates with notable colleagues such as Jun Lou and Yongkai Chen. Their combined expertise enhances the research and development efforts within their organization, fostering an environment of innovation and discovery.
Conclusion
Wei Peng's innovative work in the field of pharmaceutical development, particularly with lysophosphatidic acid receptor antagonists and triazole compounds, showcases his dedication to improving healthcare solutions. His patents reflect a significant advancement in the treatment of LPAR1-related diseases, highlighting the
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile